Coronavirus disease 19 (COVID-19) has posed serious threats to the general population. To relieve the crisis, a comparison of drug effects against COVID-19 is instructive. Between January 27, 2020 and March 21, 2020, a total of 333 patients treated with arbidol, corticosteroids, hydroxychloroquine, lopinavir/ritonavir, or oseltamivir monotherapy, having definite outcomes and serological antibody detection results, were retrospectively analyzed. The hydroxychloroquine group had a significantly reduced duration of hospital stay than the arbidol and corticosteroids groups. The oseltamivir group had a significantly shorter length of hospital stay than the arbidol, corticosteroids, and lopinavir/ritonavir groups. The hydroxychloroquine group had a significantly higher IgM titer than the other four groups and exhibited significantly higher IgG levels than the arbidol, lopinavir/ritonavir, and oseltamivir groups. Our findings indicated that hydroxychloroquine might have the potential for efficient COVID-19 management, while oseltamivir should be prudently considered in combination therapy.

冠状病毒病 19 (COVID-19) 已对普通民众构成严重威胁。为了缓解危机，比较药物对 COVID-19 的作用具有指导意义。回顾性分析2020年1月27日至2020年3月21日期间接受阿比多尔、皮质类固醇、羟氯喹、洛匹那韦/利托那韦或奥司他韦单药治疗且结局明确及血清学抗体检测结果明确的333例患者。与阿比多尔和皮质类固醇组相比，羟氯喹组的住院时间显着缩短。奥司他韦组的住院时间明显短于阿比多尔、皮质类固醇和洛匹那韦/利托那韦组。羟氯喹组的 IgM 滴度明显高于其他四组，IgG 水平明显高于阿比多尔、洛匹那韦/利托那韦和奥司他韦组。我们的研究结果表明，羟氯喹可能具有有效管理 COVID-19 的潜力，而在联合治疗中应谨慎考虑奥司他韦。